Clinical Trials Directory

We are doing this study to be an early access program to treat C3G or IC-MPGN, which may lead to damage in your kidneys, protein in your urine, high blood pressure, and swelling of your hands, feet, and ankles.

We are doing this study to identify patients who have gene changes or mutations in their tumor(s) and might be eligible for treatment using a combination of targeted therapy options. This study is called ComboMATCH (Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice).

We are doing this study to find out if a study drug called binimetinib is a safe and effective option for cancers that harbor certain genetic mutations (RAS/RAF/MEK). We want to know how well it works on its own for some cancers, and how it works in combination with another study drug called palbociclib for other cancers.

We are doing this study to compare the outcomes for women who use selumetinib alone and women who use selumetinib plus olaparib to treat endometrial or ovarian cancer. We want to know which option is better for women whose tumors harbor a mutation in a key survival pathway called KRAS.

We are doing this study to find out if combining a drug called ipatasertib with the chemotherapy drug paclitaxel can help shrink or control solid tumors that have AKT gene mutations.

We are doing this study to find out if a drug called pembrolizumab (the study drug) is a safe and effective option for people with undifferentiated pleomorphic sarcoma (UPS) or a related poorly differentiated sarcoma. We want to know if adding it to treatment with the usual drug for this type of cancer can improve results.

We are doing this study to find out the safety and effectiveness of Tumor Treating Fields (TTFields, 200 kHz) delivered by the Optune® device. We want to know if this experimental procedure can improve results for people who are being treated for GBM. We will compare how well this procedure works when it is given along with 2 different types of drug therapies.

We are doing this study to find out if an experimental drug called efgartigimod (the study drug) is a safe and effective option for people experiencing kidney rejection. We want to know if it can decrease antibody-mediated rejection following a transplant by removing the antibodies that target and damage the cells of the donated kidney.